Researchers identify GPNMB as a driver of Parkinson’s disease spread and demonstrate that monoclonal antibodies can block its activity to slow neurodegeneration.
Summary: Researchers identified a promising new target for slowing the progression of Parkinsons disease (PD). The study demonstrates that a protein called GPNMB (glycoprotein nonmetastatic melanoma … [+8466 chars]